Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 9/20 | 0.42 |
| ▸ | WNT3A | P56704 | 3/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16537142 | 0.94 | KIT (0.43) | KITWNT3AFLT3CACNA1HKDM4E | |
| SCHEMBL16536796 | 0.87 | KIT (0.49) | KITWNT3AFLT3CACNA1HKDM4E | |
| SCHEMBL16537004 | 0.85 | KIT (0.48) | KITWNT3AFLT3CACNA1HKDM4E | |
| SCHEMBL16536174 | 0.84 | KIT (0.48) | KITWNT3AFLT3CACNA1HKDM4E | |
| SCHEMBL16536795 | 0.80 | KIT (0.62) | KITFLT3CACNA1HKDM4E | |
| SCHEMBL16540160 | 0.79 | PDE4A (0.42) | CACNA1H | |
| SCHEMBL16536344 | 0.76 | RET (0.49) | KITWNT3ACACNA1HKDM4E | |
| SCHEMBL16536754 | 0.72 | KIT (0.59) | KITFLT3 | |
| SCHEMBL16536972 | 0.70 | KIT (0.65) | KITFLT3BRAFKDM4E | |
| Formic Acid SCHEMBL16536759 | 0.70 | KIT (0.56) | KITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725465-B2 | Biaryl acetamide compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3039021-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015031613-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | ERBB2, ERBB3, AADAC | KIT 1109/4885WNT3A 2952/4885FLT3 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.